Table 6.
Five-Year Rates of Advanced AMD and (for Eyes That Did Not Progress to Advanced AMD) Rates of Progression From Scale Steps 1 to 6 to Steps 7 to 9 for Right and Left Eyes of Participants Free of Advanced AMD in Both Eyes at Baseline
|
Pigment Abnormalities: Increased Pigment Depigmentation Geographic Atrophy |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0 | ≥Q | ≥0 | ≥0 | ≥0 | ≥0 | |||||||
| 0 | 0 | ≥Q, <I-2 | ≥I-2, <0.5 DA | ≥0.5 DA | ≥0 | |||||||
|
0 |
0 |
0 |
0 |
0 |
≥Q |
Total |
||||||
| Drusen Area | R | L | R | L | R | L | R | L | R | L | R | L |
| <C-1 | ||||||||||||
| No. of eyes | 1430 | 1463 | 68 | 66 | 17 | 19 | 5 | 3 | 2 | 1 | 1522 | 1552 |
| To steps 7–9, % | 0.3 | 0.7 | 8.8 | 6.1 | 5.9 | 42.1 | NA | NA | NA | NA | NA | NA |
| AdvAMD, % | 0.3 | 0.3 | 0.0 | 0.0 | 5.9 | 5.3 | 60.0 | 0.0 | 50.0 | 0.0 | 0.6 | 0.3 |
| ≥C-1, <C-2 | ||||||||||||
| No. of eyes | 367 | 398 | 78 | 71 | 13 | 12 | 4 | 5 | 1 | 5 | 463 | 491 |
| To steps 7–9, % | 2.2 | 2.5 | 12.8 | 9.9 | 23.1 | 16.7 | NA | NA | NA | NA | NA | NA |
| AdvAMD, % | 1.1 | 0.3 | 3.8 | 5.6 | 0.0 | 8.3 | 75.0 | 40.0 | 100.0 | 40.0 | 2.4 | 2.0 |
| ≥C-2, <I-2 | ||||||||||||
| No. of eyes | 206 | 172 | 74 | 63 | 26 | 11 | 8 | 6 | 1 | 0 | 315 | 252 |
| To steps 7–9, % | 2.9 | 5.2 | 20.3 | 23.8 | 34.6 | 36.4 | NA | NA | NA | NA | NA | NA |
| AdvAMD, % | 2.9 | 0.6 | 4.1 | 9.5 | 3.8 | 18.2 | 37.5 | 33.3 | 0.0 | 0.0 | 4.1 | 4.4 |
| ≥I-2, < O-2 | ||||||||||||
| No. of eyes | 155 | 151 | 78 | 73 | 15 | 16 | 9 | 12 | 2 | 3 | 259 | 255 |
| To steps 7–9, % | 12.9 | 18.5 | 37.2 | 31.5 | 60.0 | 37.5 | NA | NA | NA | NA | NA | NA |
| AdvAMD, % | 1.9 | 6.6 | 10.3 | 5.5 | 13.3 | 12.5 | 55.6 | 0.0 | 50.0 | 66.7 | 7.3 | 7.1 |
| ≥O-2, <0.5 DA | ||||||||||||
| No. of eyes | 98 | 94 | 61 | 76 | 12 | 8 | 8 | 7 | 7 | 4 | 186 | 189 |
| To steps 7–9, % | 39.8 | 40.4 | 67.2 | 53.9 | NA | NA | NA | NA | NA | NA | NA | NA |
| AdvAMD, % | 3.1 | 5.3 | 18.0 | 18.4 | 41.7 | 50.0 | 50.0 | 57.1 | 42.9 | 75.0 | 14.0 | 15.9 |
| ≥0.5 DA | ||||||||||||
| No. of eyes | 156 | 159 | 227 | 241 | 48 | 48 | 14 | 13 | 22 | 14 | 467 | 475 |
| To steps 7–9, % | 62.2 | 59.7 | NA | MA | NA | NA | NA | NA | NA | NA | NA | NA |
| AdvAMD, % | 11.5 | 12.6 | 27.8 | 27.0 | 47.9 | 56.3 | 50.0 | 53.8 | 50.0 | 64.3 | 26.1 | 26.9 |
| Total | ||||||||||||
| No. of eyes | 2412 | 2437 | 586 | 590 | 131 | 114 | 48 | 46 | 35 | 27 | 3212 | 3214* |
| To steps 7–9, % | 7.3 | 7.8 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| AdvAMD, % | 1.6 | 1.7 | 15.0 | 15.8 | 24.4 | 32.5 | 52.1 | 32.6 | 48.6 | 59.3 | 6.2 | 6.3 |
Abbreviations: AdvAMD, advanced AMD; AMD, age-related macular degeneration; DA, disc area; NA, not applicable; L, left eye; R, right eye.
*
For 2 of the 3214 patients whose left eyes are included in the table, the grading for the right eye was “cannot grade” for 1 or more characteristics at either the baseline or the 5-year visit.
Scale Steps: 1 2 3 4 5 6 7 8 9